459 related articles for article (PubMed ID: 27509411)
1. Primary cutaneous CD30(+) lymphoproliferative disorders.
Wieser I; Tetzlaff MT; Torres Cabala CA; Duvic M
J Dtsch Dermatol Ges; 2016 Aug; 14(8):767-82. PubMed ID: 27509411
[TBL] [Abstract][Full Text] [Related]
2. CD30-Positive Lymphoproliferative Disorders.
Nikolaenko L; Zain J; Rosen ST; Querfeld C
Cancer Treat Res; 2019; 176():249-268. PubMed ID: 30596222
[TBL] [Abstract][Full Text] [Related]
3. Mycosis Fungoides Associated With Lesions in the Spectrum of Primary Cutaneous CD30+ Lymphoproliferative Disorders: The Same Process or 3 Coexisting Lymphomas?
Cieza-Díaz DE; Prieto-Torres L; Rodríguez-Pinilla SM; Córdoba Mascuñano R; Manso Alonso R; Machan S; Piris Pinilla MÁ; Requena Caballero L
Am J Dermatopathol; 2019 Nov; 41(11):846-850. PubMed ID: 30946099
[TBL] [Abstract][Full Text] [Related]
4. Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin.
de la Garza Bravo MM; Patel KP; Loghavi S; Curry JL; Torres Cabala CA; Cason RC; Gangar P; Prieto VG; Medeiros LJ; Duvic M; Tetzlaff MT
Hum Pathol; 2015 Apr; 46(4):558-69. PubMed ID: 25666664
[TBL] [Abstract][Full Text] [Related]
5. Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.
Gill RPK; Gantchev J; Martínez Villarreal A; Ramchatesingh B; Netchiporouk E; Akilov OE; Ødum N; Gniadecki R; Koralov SB; Litvinov IV
Cells; 2022 Feb; 11(4):. PubMed ID: 35203244
[TBL] [Abstract][Full Text] [Related]
6. Practical Management of CD30⁺ Lymphoproliferative Disorders.
Hughey LC
Dermatol Clin; 2015 Oct; 33(4):819-33. PubMed ID: 26433852
[TBL] [Abstract][Full Text] [Related]
7. Galectin-3 Expression in Primary Cutaneous CD30-Positive Lymphoproliferative Disorders and Transformed Mycosis Fungoides.
Mitteldorf C; Robson A; Tronnier M; Pfaltz MC; Kempf W
Dermatology; 2015; 231(2):164-70. PubMed ID: 26111483
[TBL] [Abstract][Full Text] [Related]
8. Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review.
Di Raimondo C; Parekh V; Song JY; Rosen ST; Querfeld C; Zain J; Martinez XU; Abdulla FR
Curr Hematol Malig Rep; 2020 Aug; 15(4):333-342. PubMed ID: 32435988
[TBL] [Abstract][Full Text] [Related]
9. [Primary cutaneous lymphoma-a case series of 163 patients].
Nashan D; Friedrich CM; Geissler E; Schmitt-Graeff A; Klein F; Meiss F
Hautarzt; 2018 Dec; 69(12):1014-1020. PubMed ID: 29881891
[TBL] [Abstract][Full Text] [Related]
10. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin.
DeCoteau JF; Butmarc JR; Kinney MC; Kadin ME
Blood; 1996 Apr; 87(8):3437-41. PubMed ID: 8605362
[TBL] [Abstract][Full Text] [Related]
11. A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders.
Kempf W
Semin Diagn Pathol; 2017 Jan; 34(1):22-35. PubMed ID: 27993440
[TBL] [Abstract][Full Text] [Related]
12. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders.
Kempf W; Levi E; Kamarashev J; Kutzner H; Pfeifer W; Petrogiannis-Haliotis T; Burg G; Kadin ME
J Cutan Pathol; 2002 May; 29(5):295-300. PubMed ID: 12100631
[TBL] [Abstract][Full Text] [Related]
13. Localized lymphomatoid papulosis: Unilesional lymphomatoid papulosis, regional lymphomatoid papulosis, and persistent agmination of lymphomatoid papulosis.
Magro CM; Mo JH; Telang G
Clin Dermatol; 2022; 40(6):622-638. PubMed ID: 35907581
[TBL] [Abstract][Full Text] [Related]
14. CD8-positive lymphomatoid papulosis (type D): Some lesions may lack CD30 expression and overlap histologically with mycosis fungoides.
Simo OC; Warren SJ; Mark L; Hoffmann K; Alomari AK
Int J Dermatol; 2019 Jul; 58(7):800-805. PubMed ID: 30520526
[TBL] [Abstract][Full Text] [Related]
15. Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients.
Wieser I; Oh CW; Talpur R; Duvic M
J Am Acad Dermatol; 2016 Jan; 74(1):59-67. PubMed ID: 26518172
[TBL] [Abstract][Full Text] [Related]
16. Histopathological aspects and differential diagnosis of CD8 positive lymphomatoid papulosis.
Marschalkó M; Gyöngyösi N; Noll J; Károlyi Z; Wikonkál N; Hársing J; Kuroli E; Csomor J; Matolcsy A; Sarolta K; Szepesi Á
J Cutan Pathol; 2016 Nov; 43(11):963-973. PubMed ID: 27461449
[TBL] [Abstract][Full Text] [Related]
17. CD30-positive lymphoproliferative disorders-An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre.
Bhabha FK; McCormack C; Campbell BA; Lade S; Buelens O; Van Der Weyden C; Prince HM
Australas J Dermatol; 2023 May; 64(2):194-203. PubMed ID: 36892928
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD44 and CD44v6 in primary cutaneous CD30 positive T-cell lymphoproliferative disorders.
Liang X; Smoller BR; Golitz LE
J Cutan Pathol; 2002 Sep; 29(8):459-64. PubMed ID: 12207739
[TBL] [Abstract][Full Text] [Related]
19. Multiple cutaneous lymphoproliferative disorders showing a retained tumor clone by T-cell receptor gene rearrangement analysis: a case series of four patients and review of the literature.
Stowman AM; Hsia LL; Kanner WA; Mahadevan MS; Bullock GC; Patterson JW
Int J Dermatol; 2016 Feb; 55(2):e62-71. PubMed ID: 26266670
[TBL] [Abstract][Full Text] [Related]
20. Nitrogen mustard gel-induced inflammation triggers lymphomatoid papulosis in patients with mycosis fungoides.
Trager MH; Chen C; Husain S; Geskin LJ
J Dermatol; 2020 May; 47(5):546-550. PubMed ID: 32100361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]